Page 2 - Nuclear Countermeasures Program News Today

RedHill Biopharma Ltd (NASDAQ: RDHL) shares are down after the company announced a registered direct offering of 1.3 million American Depositary Shares, each ADS representing four hundred (400) ordinary shares, at a purchase price of $1.35 per ADS (or ADS equivalent), in a 

Opaganib awarded a further $1.7 million in U.S. Government funding for development as a medical countermeasure for gastrointestinal acute radiation syndrome...

RedHill Biopharma Ltd.’s stock soared 10% premarket after the company said it has received a further $1.7 million in U.S. government funding for its partner,...

By Chris Wack RedHill Biopharma said Friday that its opaganib has been awarded a further $1.7 million in U.S. government funding, via a Small Business...

Q1/23 Talicia net revenues of $3.4 million; Cash balance of $28.8 million as of March 31, 2023[1]; Extinguishment of all debt obligations in exchange for the...

RedHill has elected to terminate RHB-204s U.S. Phase 3 study for Non-tuberculosis Mycobacteria disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107... | May 22, 2023

A first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body has begun. The trial is testing the safety, tolerability and processing in the body of escalating doses of the investigational drug product HOPO 14-1 in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the Phase 1 trial, which is sponsored and conducted by SRI International of Menlo Park, Ca...

Having extinguished all debt and significantly reduced cost-base, RedHill is now focused on late-stage pipeline advancement, in collaboration with U.S. and...

The National Institutes of Healths (NIH) Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for testing via their radiation medical...

Investegate announcements from RedHill Biopharma, RDHL Opaganib Selected by NIH RNCP For Development